dc.contributor.author | Köse, Duygu | |
dc.contributor.author | Köse, Ahmet | |
dc.contributor.author | Halıcı, Zekai | |
dc.contributor.author | Gürbüz, Muhammet Ali | |
dc.contributor.author | Maman, Adem | |
dc.contributor.author | Yayla, Muhammed | |
dc.date.accessioned | 2022-09-29T08:25:00Z | |
dc.date.available | 2022-09-29T08:25:00Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.uri | https://dergipark.org.tr/tr/download/article-file/1775561 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12868/1713 | |
dc.description.abstract | Aim: Melatonin promoted osteoblast differentiation and causes an increase in levels
of markers of bone differentiation and proliferation. Ramelteon (RAMEL) activates
melatonin receptors and binds to these receptors as non-selective. In this study, we
investigated the preventive effects of the melatonin agonist RAMEL on osteoporosis
by radiological, histological, and molecularly.
Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP),
Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animals
underwent bilateral ovariectomy. RAMEL was administered orally once a day in the
prophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy.
Results: Fourteen weeks after ovariectomy, there was a significant reduction in
femoral bone mineral density (BMD) (g/cm2) in the OP group compared to the control
group. Compared to the OP group, RAMEL treatment significantly increased the BMD
level (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2
(RUNX2) mRNA levels were significantly lower in the OP group than in the control
group (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in the
RAMEL treatment groups than in the OP group (p<0.05).
Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, a
peripheral melatonin agonist, can be used to prevent osteoporosis. | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.30565/medalanya.939161 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Ramelteon, melatonin, osteoporosis, bone | en_US |
dc.subject | Ramelteon | en_US |
dc.subject | Melatonin | en_US |
dc.subject | Osteoporosis | en_US |
dc.subject | Bone | en_US |
dc.title | Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis | en_US |
dc.type | article | en_US |
dc.contributor.department | ALKÜ | en_US |
dc.identifier.volume | 5 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 164 | en_US |
dc.identifier.endpage | 170 | en_US |
dc.relation.journal | Acta Medica Alanya | en_US |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Başka Kurum Yazarı | en_US |